Model-free parameters from dynamic contrast-enhanced-MRI: Sensitivity to EES volume fraction and bolus timing

Journal of Magnetic Resonance Imaging

Volumn 24, Issue 3, 2006, Pages 586-594

  Jesberger, John A ^a   Rafie, Niusha ^a   Duerk, Jeffrey L ^a,b,c   Sunshine, Jeffrey L ^a   Mendez, Matthew ^b   Remick, Scot C ^a   Lewin, Jonathan S ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Angiogenesis; Diffusible tracers; Dynamic contrast enhanced MRI; Methodology; Perfusion imaging

Indexed keywords

ANGIOGENESIS; AREA UNDER THE CURVE; ARTICLE; COMPARTMENT MODEL; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; EXTRAVASCULAR SPACE; HEART MUSCLE PERFUSION; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION;

CONTRAST MEDIA; EXTRACELLULAR SPACE; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE IMAGING; MODELS, STATISTICAL; NEOVASCULARIZATION, PATHOLOGIC; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 33748255512     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.20670     Document Type: Article

References (29)

1. Taylor JS, Tofts PS, Port R, et al. MR imaging of tumor microcirculation: promise for the new millennium. J Magn Reson Imaging 1999;10:903-907.
2. Evelhoch J, Garwood M, Vigneron D, et al. Expanding the use of magnetic resonance in the assessment of tumor response to therapy: workshop report. Cancer Res 2005;65:7041-7044.
3. Leach MO, Brindle KM, Evelhoch JL, et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 2005;92:1599-1610.
4. Dowlati A, Robertson K, Cooney M, et al. A phase 1 pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002;62:3408-3416.
5. Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757-1763.
6. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972;175:409-416.
7. Denekamp J, Hill S. Angiogenic attack as a therapeutic strategy for cancer. Radiother Oncol 1991;20(Suppl 1):103-112.
8. Galbraith SM, Lodge MA, Taylor NJ, et al. Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. NMR Biomed 2002;15:132-142.
9. Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 1991;17:357-367.
10. Larsson HB, Tofts PS. Measurement of blood-brain barrier permeability using dynamic Gd-DTPA scanning-a comparison of methods. Magn Reson Med 1992;24:174-176.
11. Brix G, Henze M, Knopp MV, et al. Comparison of pharmacokinetic MRI and [18F] fluorodeoxyglucose PET in the diagnosis of breast cancer: initial experience. Eur Radiol 2001;11:2058-2070.
12. Brix G, Semmler W, Port R, Schad LR, Layer G, Lorenz WJ. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr 1991;15:621-628.
13. Kety SS. The theory and application of the exchange of inert gas at the lungs and tissues. Pharmocol Rev 1951;3:1-41.
14. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223-232.
15. Evelhoch JL, Brown T, Chenevert L, et al. Consensus recommendation for acquisition of dynamic contrast-enhanced MRI data in oncology. In: Proceedings of the 8th Annual Meeting of ISMRM, Denver, CO, USA. 2000. p 1439.
16. Reddick, WE, Langston, JW, Meyer, WH, et al. Discrete signal processing of dynamic contrast-enhanced MR imaging: statistical validation and preliminary clinical application. J Magn Reson Imaging 1994;4:397-404.
17. Moate PJ, Dougherty L, Schnall MD, Landis RJ, Boston RC. A modified logistic model to describe gadolinium kinetics in breast tumors. Magn Reson Imaging 2004;22:467-473.
18. Jesberger JA, Lewin JS, Duerk JL. Comparison of flow correlates obtained from DCE-MRI perfusion data: sensitivity to variation in the volume fraction of the extravascular extracellular space. In: Proceedings of the 10th Annual Meeting of ISMRM, Honolulu, H1, USA, 2002.
19. Evelhoch JL. Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 1999;10:254-259.
20. Brix G, Henze M, Knopp MV, et al. Comparison of pharmacokinetic MRI and [18F] fluorodeoxyglucose PET in the diagnosis of breast cancer: initial experience. Eur Radiol 2001;11:2058-2070.
21. Renkin EM. Transport of potassium-42 from blood to tissue in isolated mammalian skeletal muscles. Am J Physiol 1959;197:1205-1210.
22. Crone C. Permeability of capillaries in various organs as determined by the use of the 'indicator-diffusion' method. Acta Physiol Scand 1963;58:292-305.
23. Simpson NE, He Z, Evelhoch JL. Deuterium NMR tissue perfusion measurements using the tracer uptake approach: I. Optimization of methods. Magn Reson Med 1999;42:42-52.
24. Dale BM, Jesberger JA, Lewin JS, Hillenbrand CM, Duerk JL. Determining and optimizing the precision of quantitative measurements of perfusion from dynamic contrast enhanced MRI. J Magn Reson Imaging 2003;18:575-584.
25. Bahill AT, McDonald JD. Frequency limitations and optimal step size for the two-point central difference derivative algorithm with applications to human eye movement data. IEEE Trans Biomed Eng 1983;30:191-194.
26. Savitzky A, Golay MJE. Smoothing and differentiation of data by simplified least squares procedures. Anal Chem 1964;36:1627-1639.
27. Bartko JJ, Carpenter Jr WT. On the methods and theory of reliability. J Nerv Ment Dis 1976;163:307-317.
28. Redman BG, Esper P, Pan Q, et al. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res 2003;9:1666-1672.
29. Henderson E, Sykes J, Drost D, Weinmann HJ, Rutt BK, Lee TY. Simultaneous MRI measurement of blood flow, blood volume, and capillary permeability in mammary tumors using two different contrast agents. J Magn Reson Imaging 2000;12:991-1003.